Hilltop BioSciences

Hilltop Bio develops exosome-based cell signaling technology to reduce inflammation and provide the necessary components to restore the body's immune balance.

  • Stage Product In Market
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD
  • Founded September 2018
  • Employees 8
  • Incorporation Type C-corp
  • Website hilltopbio.com

Company Summary

Hilltop is changing the way we treat our animals, with easy-to-use therapies that help the body heal itself after injury or inflammatory disease. Our therapies are room temperature, making them one of the first regenerative therapies that our vets can keep on the shelf as they would a pharmaceutical product.

We have hit all of our milestones and 96% of vets repeat purchase within 2 months of trying the products. Currently, Hilltop is B2B.

Team

  • Amanda Drobnis

  • Mark Williams
    VP Sales and Distribution

    20 years experience in veterinary sales, bringing new products to market and leading large sales teams

  • David Dutton
    Chief Veterinary Officer

    Dr. Dutton is an equine sports medicine veterinarian with 30+ years of experience as a practice owner and treating vet. He has researched and used a variety of regenerative therapies in many different indications and brings his experiences and expertise to Hilltop Bio.

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free